台灣臨床試驗主持人資料庫|TPIDB

2016-07-01 - 2019-12-31

Phase I

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C (M7824) in subjects with metastatic or locally advanced solid tumors with expansion to selected indications in Asia

Condition/Disease

metastatic or locally advanced solid tumors
Test Drug

MSB0011359C (M7824)

Participate Sites
5Sites

Terminated5Sites

侯明模

Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2017-01-01 - 2019-11-30

Phase II

A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects with Systemic Lupus Erythematosus and Active Skin Manifestations and in Subjects with Active Cutaneous Lupus Erythematosus with or without Systemic Manifestations

Condition/Disease

1. Systemic Lupus Erythematosus and Active Skin Manifestations2. Active Cutaneous Lupus Erythematosus with or without Systemic Manifestations
Test Drug

BIIB059

Participate Sites
4Sites

Recruiting4Sites

方耀凡

Linkou Chang Gung Medical Foundation

Division of Rheumatology

2016-09-30 - 2018-12-31

Phase III

A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer′s Disease Dementia (The DAYBREAK Study)

Condition/Disease

Mild Alzheimer′s Disease
Test Drug

LY3314814

Participate Sites
10Sites

Terminated10Sites

黃錦章

Linkou Chang Gung Medical Foundation

Division of Neurology

2016-05-01 - 2018-09-30

Phase III

A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro esophageal junction

Condition/Disease

Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction
Test Drug

avelumab

Participate Sites
10Sites

Terminated9Sites

陳仁熙

Linkou Chang Gung Medical Foundation

白禮源

China Medical University Hospital-Taipei

未分科

2015-06-01 - 2018-12-31

Phase III

A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus docetaxel in subjects with non-small cell lung cancer that has progressed after a platinum-containing doublet

Condition/Disease

NSCLC
Test Drug

avelumab

Participate Sites
6Sites

Terminated6Sites

楊政達

Linkou Chang Gung Medical Foundation

2018-07-01 - 2021-12-31

Phase III

A Phase III, Randomized, Placebo Controlled, Multicenter, Double-Blind Study Comparing Toripalimab Injection (JS001) Combined With Chemotherapy Versus Placebo Combined With Chemotherapy for Recurrent or Metastatic Nasopharyngeal Cancer

Condition/Disease

Nasopharyngeal Cancer
Test Drug

JS001

Participate Sites
8Sites

Terminated7Sites

王宏銘

Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

楊慕華

Taipei Veterans General Hospital

Division of Hematology & Oncology

2018-06-15 - 2021-06-30

Phase III

An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs. Chemotherapy in Subjects with Previously Treated Locally Advanced or Metastatic Urothelial Cancer(EV-301)

Condition/Disease

Locally Advanced or Metastatic Urothelial Cancer
Test Drug

enfortumab vedotin

Participate Sites
6Sites

Recruiting5Sites

Study ended1Sites

林永昌

Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2018-07-30 - 2020-09-30

Phase III

A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of IMAB362 Plus mFOLFOX6 Compared with Placebo Plus mFOLFOX6 as First-line Treatment of Subjects with Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Condition/Disease

Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Test Drug

IMAB362

Participate Sites
9Sites

Recruiting6Sites

Terminated2Sites

陳仁熙

Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

洪逸平

Taipei Veterans General Hospital

Division of Hematology & Oncology

2017-05-01 - 2019-12-31

Phase III

Condition/Disease
Test Drug

Participate Sites
2Sites

Terminated2Sites

黃錦章

Linkou Chang Gung Medical Foundation

Division of Neurology

2018-03-01 - 2021-06-30

Phase III

A Phase 3 Multicenter, Double-Blind Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Adult Patients With Atopic Dermatitis

Condition/Disease

Atopic Dermatitis
Test Drug

Baricitinib (LY3009104)

Participate Sites
6Sites

Terminated6Sites

李婉若

Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Dermatology

Search Result

List